Plus   Neg

Stock Alert: VolitionRx Shares Rally 80% In Premarket On COVID-19 Triage Test Data

Shares of VolitionRx Ltd. (VNRX) are soaring over 80% in pre-market today, after the company announced that results from two proof of concept clinical studies using its Nu.Q assays have been submitted for peer review and would be available on BIORXIV.ORG shortly.

Cameron Reynolds, Chief Executive Officer of Volition said, "Nu.Q has shown correlation with more severe COVID-19 cases implying strong prognostic potential, and we are now focused on the completion of larger longitudinal studies that would be needed to support a potential COVID-19 product launch. If we continue to see positive results in these longitudinal studies, we aim to have a CE-marked product available on multiple platforms in 2020 and will look to launch a low-cost product that could be used in any laboratory worldwide as soon as possible thereafter."

The stock has been trading in the range of $2.22 - $6.84 for the past one year, and closed Monday's trade flat at $3.50. Currently, VNRX is trading at $6.30, up $2.81 or 80.52% in the pre-market session.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT